Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C22H23FN4O2 |
| Molecular Weight | 394.442 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@H](C1=NOC(NC(=N)N2CCOCC2)=C1)C3=CC=C(C(F)=C3)C4=CC=CC=C4
InChI
InChIKey=MYTIJGWONQOOLC-HNNXBMFYSA-N
InChI=1S/C22H23FN4O2/c1-15(17-7-8-18(19(23)13-17)16-5-3-2-4-6-16)20-14-21(29-26-20)25-22(24)27-9-11-28-12-10-27/h2-8,13-15H,9-12H2,1H3,(H2,24,25)/t15-/m0/s1
| Molecular Formula | C22H23FN4O2 |
| Molecular Weight | 394.442 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Rimacalib (SMP 114) is a prostaglandin E2 antagonist that has been evaluated for use in rheumatoid arthritis. This orally bioavailable compound is a CaMKII inhibitor developed for human use. A phase II clinical trial to compare the effects of rimacalib to placebo in patients with rheumatoid arthritis has been terminated in 2009. Rimacalib also reduces SR Ca2+ leak and was therefore suggested as a candidate drug to treat proarrhythmogenic events in human atrial cardiomyocytes and cardiomyocytes from patients with heart failure.
Originator
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:44:15 GMT 2025
by
admin
on
Mon Mar 31 18:44:15 GMT 2025
|
| Record UNII |
BZ76J3N815
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C257
Created by
admin on Mon Mar 31 18:44:15 GMT 2025 , Edited by admin on Mon Mar 31 18:44:15 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
CHEMBL2107772
Created by
admin on Mon Mar 31 18:44:15 GMT 2025 , Edited by admin on Mon Mar 31 18:44:15 GMT 2025
|
PRIMARY | |||
|
8597
Created by
admin on Mon Mar 31 18:44:15 GMT 2025 , Edited by admin on Mon Mar 31 18:44:15 GMT 2025
|
PRIMARY | |||
|
C87325
Created by
admin on Mon Mar 31 18:44:15 GMT 2025 , Edited by admin on Mon Mar 31 18:44:15 GMT 2025
|
PRIMARY | |||
|
DTXSID401351185
Created by
admin on Mon Mar 31 18:44:15 GMT 2025 , Edited by admin on Mon Mar 31 18:44:15 GMT 2025
|
PRIMARY | |||
|
215174-50-8
Created by
admin on Mon Mar 31 18:44:15 GMT 2025 , Edited by admin on Mon Mar 31 18:44:15 GMT 2025
|
PRIMARY | |||
|
BZ76J3N815
Created by
admin on Mon Mar 31 18:44:15 GMT 2025 , Edited by admin on Mon Mar 31 18:44:15 GMT 2025
|
PRIMARY | |||
|
9800765
Created by
admin on Mon Mar 31 18:44:15 GMT 2025 , Edited by admin on Mon Mar 31 18:44:15 GMT 2025
|
PRIMARY | |||
|
DB12571
Created by
admin on Mon Mar 31 18:44:15 GMT 2025 , Edited by admin on Mon Mar 31 18:44:15 GMT 2025
|
PRIMARY | |||
|
100000175055
Created by
admin on Mon Mar 31 18:44:15 GMT 2025 , Edited by admin on Mon Mar 31 18:44:15 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
